Evidence map›Paper›PMID 41061075›Full record

ArticleScience advances2025

Photoactivatable immunostimulatory nanoengineered microalgae for boosting cascade-activated antitumor immunity.

Shuiling Chen, Ming Li, Yu Zhang, Yushu Dong, Jinying Wu, Lixiang Li, Xing Guo, Xia Liu, Jianwen Hou, Shaobing Zhou

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. HAdvanced materials (Deerfield Beach, Fla.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuiling ChenInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.ORCID 0009-0002-9667-6656
Ming LiInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
Yu ZhangInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
Yushu DongInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
Jinying WuInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
Lixiang LiInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
Xing GuoInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
Xia LiuSchool of Chemistry, Southwest Jiaotong University, Chengdu 610031, China.ORCID 0000-0002-0869-783X
Jianwen HouInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.ORCID 0000-0002-9283-1412
Shaobing ZhouInstitute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.ORCID 0000-0002-6155-4010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited tumor immunogenicity and the profoundly immunosuppressive tumor microenvironment (TME) pose major challenges to effective cancer immunotherapy. Herein, we present a photoactivatable immunostimulator based on nanoengineered microalgae (PCC@AuNP) to simultaneously enhance tumor immunogenicity and remodel the TME. Mechanistically, photocatalytically generated hydrogen induces robust immunogenic cell death by triggering severe endoplasmic reticulum stress and mitochondrial dysfunction. Concurrently, photosynthetic oxygen production and photocatalytic lactic acid depletion collaboratively alleviate immunosuppression within the TME, thereby enhancing cytotoxic T lymphocyte activity by reducing the infiltration of immunosuppressive cells and promoting the repolarization of tumor-associated macrophages from the M2 to the M1 phenotype. In vivo studies demonstrate that PCC@AuNP not only eradicates primary tumors but also elicits potent systemic antitumor immunity against distant lesions, without observable toxicity to healthy tissues. Collectively, this innovative PCC@AuNP platform offers a safe and effective therapeutic strategy, heralding a pioneering era of cascade-augmented gas-driven cancer immunotherapy with superior precision and biosafety.

Indexed as

Adjuvants, ImmunologicMicroalgaeNeoplasmsAnimalsCell Line, TumorGoldHumansImmunotherapyMiceT-Lymphocytes, CytotoxicTumor MicroenvironmentAdjuvants, ImmunologicGold

Identifiers

PMID41061075
PMCPMC12507002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.